| Sumario: | Introduction: Glaucoma is a leading cause of blindness and represents a significant global health and economic concern. Prostaglandin analogs such as latanoprost - which act to reduce intraocular pressure by enhancing uveoscleral flow and slow the development and progression of glaucoma - are recommended as a first-line monotherapy. Areas covered: We review recent efficacy and safety data for latanoprost, both alone and in combination therapy, and vs. other prostaglandin analogs, focusing on the tolerability and adherence to the drug and the subsequent impact on patient-perceived quality of life. Relevant studies were identified by an electronic literature search using MEDLINE PubMed, and current global glaucoma guidelines were reviewed. Expert commentary: Prostaglandin analogs represent the cornerstone in glaucoma therapy. Individual studies demonstrate differences in efficacy between prostaglandin analogs, but within-class differences are generally small - and, on balance, latanoprost presents a good efficacy-safety profile. Low adverse event rates result in greater persistence and improved quality of life for patients. Further, a latanoprost/β-blocker combination represents an efficacious therapeutic alternative where monotherapy does not sufficiently reduce intraocular pressure. However, high-quality randomized controlled trials are required to provide further information regarding fixed-dose combination vs. unfixed combination treatment regimens.
|
|---|